RemeGen Co., Ltd. (9995.HK)
HKD 15.52
(-0.26%)
HKD 15.52
(-0.26%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.51 Billion CNY | -51.45% |
| 2022 | -997.83 Million CNY | -461.2% |
| 2021 | 276.25 Million CNY | 137.99% |
| 2020 | -727.09 Million CNY | -53.42% |
| 2019 | -473.93 Million CNY | -76.52% |
| 2018 | -268.48 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -431.53 Million CNY | -23.68% |
| 2024 Q1 | -348.92 Million CNY | 27.41% |
| 2023 Q3 | -327.22 Million CNY | 13.79% |
| 2023 FY | -1.51 Billion CNY | -51.45% |
| 2023 Q4 | -480.64 Million CNY | -46.89% |
| 2023 Q2 | -379.58 Million CNY | -17.24% |
| 2023 Q1 | -323.77 Million CNY | -4.24% |
| 2022 Q3 | -199.09 Million CNY | 1.58% |
| 2022 Q1 | -286.83 Million CNY | -129.74% |
| 2022 Q2 | -202.29 Million CNY | 29.47% |
| 2022 FY | -997.83 Million CNY | -461.2% |
| 2022 Q4 | -310.61 Million CNY | -56.01% |
| 2021 Q3 | -244.21 Million CNY | 5.91% |
| 2021 Q1 | -184.48 Million CNY | 17.64% |
| 2021 FY | 276.25 Million CNY | 137.99% |
| 2021 Q2 | -259.56 Million CNY | -40.7% |
| 2021 Q4 | 964.51 Million CNY | 494.94% |
| 2020 Q3 | -223.99 Million CNY | -49.09% |
| 2020 Q4 | -223.99 Million CNY | 0.0% |
| 2020 Q2 | -150.24 Million CNY | -50.86% |
| 2020 Q1 | -99.59 Million CNY | 12.83% |
| 2020 FY | -727.09 Million CNY | -53.42% |
| 2019 Q1 | -87.76 Million CNY | 25.95% |
| 2019 FY | -473.93 Million CNY | -76.52% |
| 2019 Q4 | -114.25 Million CNY | 0.0% |
| 2019 Q3 | -114.25 Million CNY | -0.21% |
| 2019 Q2 | -114.01 Million CNY | -29.91% |
| 2018 Q4 | -118.51 Million CNY | 0.0% |
| 2018 Q2 | -77.5 Million CNY | 0.0% |
| 2018 Q1 | -77.5 Million CNY | 0.0% |
| 2018 FY | -268.48 Million CNY | 0.0% |
| 2017 Q4 | -77.5 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 70.87 Million HKD | 2232.215% |
| CK Life Sciences Int'l., (Holdings) Inc. | 17.25 Million HKD | 8860.748% |